Telisotuzumab vedotin  (Synonyms: ABBV-399)

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research^[1][2][3].

ABBV-399 demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ABBV-399 effectively inhibits tumor growth and overcomes resistance to small molecule MET inhibitors in xenograft models resistant to other c-Met inhibitors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145000 (average)

1714088-51-3

Liquid

Colorless to light yellow

[Telisotuzumab vedotin]

Shipping with dry ice.

-80°C, protect from light

• [1]. Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306.  [Content Brief]

  [2]. Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115.  [Content Brief]

  [3]. Jieyi Wang, et al. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res (2017) 23 (4): 992-1000.